Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Human Genetics Center, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
Brief Bioinform. 2018 May 1;19(3):450-460. doi: 10.1093/bib/bbw127.
Assessing the impact of kinase in gene fusion is essential for both identifying driver fusion genes (FGs) and developing molecular targeted therapies. Kinase domain retention is a crucial factor in kinase fusion genes (KFGs), but such a systematic investigation has not been done yet. To this end, we analyzed kinase domain retention (KDR) status in chimeric protein sequences of 914 KFGs covering 312 kinases across 13 major cancer types. Based on 171 kinase domain-retained KFGs including 101 kinases, we studied their recurrence, kinase groups, fusion partners, exon-based expression depth, short DNA motifs around the break points and networks. Our results, such as more KDR than 5'-kinase fusion genes, combinatorial effects between 3'-KDR kinases and their 5'-partners and a signal transduction-specific DNA sequence motif in the break point intronic sequences, supported positive selection on 3'-kinase fusion genes in cancer. We introduced a degree-of-frequency (DoF) score to measure the possible number of KFGs of a kinase. Interestingly, kinases with high DoF scores tended to undergo strong gene expression alteration at the break points. Furthermore, our KDR gene fusion network analysis revealed six of the seven kinases with the highest DoF scores (ALK, BRAF, MET, NTRK1, NTRK3 and RET) were all observed in thyroid carcinoma. Finally, we summarized common features of 'effective' (highly recurrent) kinases in gene fusions such as expression alteration at break point, redundant usage in multiple cancer types and 3'-location tendency. Collectively, our findings are useful for prioritizing driver kinases and FGs and provided insights into KFGs' clinical implications.
评估激酶在基因融合中的作用对于鉴定驱动融合基因(FG)和开发分子靶向治疗至关重要。激酶结构域保留是激酶融合基因(KFG)中的一个关键因素,但尚未对此进行系统研究。为此,我们分析了涵盖 13 种主要癌症类型中 312 种激酶的 914 个 KFG 的嵌合蛋白序列中的激酶结构域保留(KDR)状态。基于包括 101 种激酶的 171 个激酶结构域保留的 KFG,我们研究了它们的重现性、激酶组、融合伙伴、基于外显子的表达深度、断点周围的短 DNA 基序和网络。我们的结果表明,与 5'-激酶融合基因相比,KDR 较多,3'-KDR 激酶与其 5'-伙伴之间的组合效应以及断点内含子序列中的信号转导特异性 DNA 序列基序,支持癌症中 3'-激酶融合基因的正选择。我们引入了一个频率度(DoF)评分来衡量一个激酶的可能的 KFG 数量。有趣的是,DoF 评分较高的激酶在断点处往往会经历强烈的基因表达改变。此外,我们的 KDR 基因融合网络分析揭示了具有最高 DoF 评分的六个激酶(ALK、BRAF、MET、NTRK1、NTRK3 和 RET)都在甲状腺癌中观察到。最后,我们总结了基因融合中“有效”(高重现性)激酶的常见特征,如断点处的表达改变、在多种癌症类型中的冗余使用以及 3'-位置倾向。总之,我们的研究结果有助于确定驱动激酶和 FG 的优先级,并深入了解 KFG 的临床意义。